The origin of Novo Nordisk A/S is not a single founding moment but a complex collision of scientific discovery, Danish industrial ambition, and the brutal economics of the global insulin market. The story begins in 1923 when August Krogh, a Danish Nobel laureate in physiology, returned from a trip to Canada where he had met Frederick Banting and Charles Best, the discoverers of insulin. Krogh secured the licensing rights to produce insulin for the Scandinavian countries, founding the Nordisk Insulinlaboratorium in Copenhagen with the assistance of Hans Christian Hagedorn, a pioneering physician who developed the first prolonged-acting insulin formulations. Simultaneously, in 1925, a group of Danish physicians and chemists founded Novo Terapeutisk Laboratorium, led by Harald Pedersen, to produce insulin and other biological products. For over six decades, Nordisk and Novo operated as fierce competitors, both growing into massive biological manufacturers through internal discovery and aggressive acquisitions. Nordisk focused on purification and prolonged-action insulins, while Novo pioneered the use of recombinant DNA technology to produce human insulin. However, by the late 1980s, both companies were facing a crisis. The cost of developing new biological drugs had skyrocketed, the European market was heavily regulated, and the global insulin industry was undergoing a wave of massive consolidations led by US giants like Eli Lilly. In 1989, the boards of Novo Industri and Nordisk Insulinlaboratorium made the radical decision to merge their operations into a single entity, creating Novo Nordisk, a name that reflected the combined heritage of the two百年old Danish companies. The merger was valued at approximately $1.5 billion and was billed as a merger of equals, but the reality was a desperate attempt to achieve the scale necessary to survive in the new era of recombinant biologics. The integration was notoriously difficult. The two companies had vastly different corporate cultures: Novo was known for its aggressive, technology-driven approach, while Nordisk was more research-oriented and conservative. The new management team, led by Steen Riis Sørensen, immediately faced the task of cutting thousands of jobs, closing redundant manufacturing facilities, and rationalizing a product portfolio that had massive overlap. The early years of Novo Nordisk were marked by constant restructuring and a series of high-profile acquisitions designed to fill pipeline gaps, including the purchase of Genentech's insulin production rights and the expansion into hemophilia and growth hormone therapies. It was not until the appointment of Lars Rebien Sørensen as CEO in 2000 that the company began to find its strategic footing, focusing on next-generation insulin analogs like Insulin aspart (NovoLog) and Insulin detemir (Levemir), which established Novo Nordisk as a global leader in diabetes care. However, the reliance on insulin analogs eventually became a burden, as the patents expired and biosimilar competition eroded margins. This led to the final, defining chapter of the origin story: the decision by Lars Fruergaard Jørgensen, who became CEO in 2017, to pivot aggressively toward GLP-1 receptor agonists and obesity therapeutics, effectively completing the transformation from a 20th-century insulin manufacturer to a 21st-century incretin and metabolic disease powerhouse.